Natamycin
DrugBank ID: DB00826
Summary
| Metric | Value |
|---|---|
| Total Predictions | 50 |
| KG+DL (Dual Validated) | 1 |
| DL Only | 49 |
| KG Only | 0 |
Predictions
| Indication | Score | Source |
|---|---|---|
| vulvovaginal candidiasis | 0.9997 | DL |
| candidiasis | 0.9986 | DL |
| vulvitis | 0.9981 | DL |
| vulvovaginitis | 0.9978 | DL |
| trichomonal vulvovaginitis | 0.9974 | DL |
| postmenopausal atrophic vaginitis | 0.9966 | DL |
| ulceration of vulva | 0.9964 | DL |
| vulvar neoplasm | 0.9963 | DL |
| vaginitis (disease) | 0.9959 | DL |
| tinea nigra | 0.9934 | DL |
| oral candidiasis | 0.9930 | DL |
| vaginal discharge | 0.9927 | DL |
| commissural lip fistula | 0.9922 | DL |
| bacterial vaginosis | 0.9921 | DL |
| burning mouth syndrome | 0.9921 | DL |
| oral leukoedema | 0.9921 | DL |
| osteoradionecrosis of the mandible | 0.9920 | DL |
| leukoplakia of vagina | 0.9920 | DL |
| herpetic vulvovaginitis | 0.9909 | DL |
| mycotic corneal ulcer | 0.9903 | KG+DL |
| dermatophytosis | 0.9897 | DL |
| anogenital human papillomavirus infection | 0.9875 | DL |
| fungal infectious disease | 0.9848 | DL |
| breast fibrocystic disease | 0.9826 | DL |
| apocrine adenosis of breast | 0.9798 | DL |
| blunt duct adenosis of breast | 0.9798 | DL |
| oral hairy leukoplakia | 0.9778 | DL |
| salivary gland disease | 0.9752 | DL |
| tongue disease | 0.9751 | DL |
| benign mammary dysplasia | 0.9751 | DL |
| immunodeficiency due to a genetic complement cascade protein anomaly | 0.9647 | DL |
| T-cell immunodeficiency with epidermodysplasia verruciformis | 0.9644 | DL |
| familial isolated congenital asplenia | 0.9608 | DL |
| breast abscess | 0.9604 | DL |
| fat necrosis of breast | 0.9604 | DL |
| epidermodysplasia verruciformis | 0.9582 | DL |
| lactation disease | 0.9563 | DL |
| common wart | 0.9555 | DL |
| neoplasm of jaw | 0.9495 | DL |
| breast adenosis | 0.9492 | DL |
| autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity | 0.9425 | DL |
| primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | 0.9423 | DL |
| piedra | 0.9298 | DL |
| varicella zoster infection | 0.9132 | DL |
| sequela of COVID-19 | 0.8799 | DL |
| herpes zoster | 0.8789 | DL |
| post-infectious neuralgia | 0.8762 | DL |
| hepatitis C induced liver cirrhosis | 0.8681 | DL |
| infective vaginitis | 0.8631 | DL |
| vulvar inverted follicular keratosis | 0.8532 | DL |
External Links
Disclaimer
Predictions are for research purposes only and do not constitute medical advice.
Predictions are for research purposes only and do not constitute medical advice.